[go: up one dir, main page]

WO1988006625A3 - Arginine-depleted human tumor necrosis factor - Google Patents

Arginine-depleted human tumor necrosis factor Download PDF

Info

Publication number
WO1988006625A3
WO1988006625A3 PCT/US1988/000183 US8800183W WO8806625A3 WO 1988006625 A3 WO1988006625 A3 WO 1988006625A3 US 8800183 W US8800183 W US 8800183W WO 8806625 A3 WO8806625 A3 WO 8806625A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
necrosis factor
tumor necrosis
muteins
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/000183
Other languages
French (fr)
Other versions
WO1988006625A2 (en
Inventor
David F Mark
Leo S Lin
James W Thomson
Ralph Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of WO1988006625A2 publication Critical patent/WO1988006625A2/en
Publication of WO1988006625A3 publication Critical patent/WO1988006625A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Muteins of tumor necrosis factor (TNF) which are arginine depleted are biologically active and have superior handling properties. Particularly preferred are deletions of, and substitutions by, neutral or acidic amino acids for the arginine residues at positions (2 and 6) of mature TNF. These muteins have higher homogeneity when subjected to isoelectric focusing. Deletion and substitution of arginine at positions (31 and 32) results in TNF muteins which are stable to the action of proteases.
PCT/US1988/000183 1987-02-26 1988-01-25 Arginine-depleted human tumor necrosis factor Ceased WO1988006625A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1922187A 1987-02-26 1987-02-26
US019,221 1987-02-26

Publications (2)

Publication Number Publication Date
WO1988006625A2 WO1988006625A2 (en) 1988-09-07
WO1988006625A3 true WO1988006625A3 (en) 1988-10-20

Family

ID=21792071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/000183 Ceased WO1988006625A2 (en) 1987-02-26 1988-01-25 Arginine-depleted human tumor necrosis factor

Country Status (2)

Country Link
AU (1) AU1346488A (en)
WO (1) WO1988006625A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843534A1 (en) * 1988-12-23 1990-07-12 Basf Ag NEW TNF POLYPEPTIDES
FR2651130B1 (en) * 1989-08-23 1991-12-13 Roussel Uclaf SEQUENCE OF ANTI-SENSE OLIGONUCLEOTIDES, ANTI-RNA MESSAGE OF TNF ALPHA, METHOD OF PREPARATION, APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS.
JP3203599B2 (en) * 1989-10-24 2001-08-27 カイロン コーポレイション Infectious protein delivery system
JPH05255393A (en) * 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd Polypeptide
ATE141093T1 (en) * 1990-09-21 1996-08-15 Ishihara Sangyo Kaisha POLYPEPTIDE
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
KR970005042B1 (en) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 Tumor Necrosis Factor-Alpha Mutein
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
IL120979A0 (en) * 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
PL2953634T3 (en) 2013-02-07 2021-11-22 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
RU2758139C2 (en) 2016-11-09 2021-10-26 Филоджен С.П.А. Il2 and mutant tnf immunoconjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155549A2 (en) * 1984-03-06 1985-09-25 Dainippon Pharmaceutical Co., Ltd. DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
EP0168214A2 (en) * 1984-07-05 1986-01-15 Genentech, Inc. Tumor necrosis factor, methods for its preparation, compositions containing it, DNA encoding it and assay method using such DNA
WO1986002381A1 (en) * 1984-10-15 1986-04-24 Cetus Corporation Human tumor necrosis factor
WO1986004606A1 (en) * 1985-02-07 1986-08-14 Cetus Corporation Cysteine-depleted muteins of biologically active human tumor necrosis factor proteins
EP0247906A2 (en) * 1986-02-04 1987-12-02 Mizuno, Den'Ichi DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155549A2 (en) * 1984-03-06 1985-09-25 Dainippon Pharmaceutical Co., Ltd. DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
EP0168214A2 (en) * 1984-07-05 1986-01-15 Genentech, Inc. Tumor necrosis factor, methods for its preparation, compositions containing it, DNA encoding it and assay method using such DNA
WO1986002381A1 (en) * 1984-10-15 1986-04-24 Cetus Corporation Human tumor necrosis factor
WO1986004606A1 (en) * 1985-02-07 1986-08-14 Cetus Corporation Cysteine-depleted muteins of biologically active human tumor necrosis factor proteins
EP0247906A2 (en) * 1986-02-04 1987-12-02 Mizuno, Den'Ichi DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides

Also Published As

Publication number Publication date
WO1988006625A2 (en) 1988-09-07
AU1346488A (en) 1988-09-26

Similar Documents

Publication Publication Date Title
HK102192A (en) Human tumor necrosis factor and dna therefor
EP0336760A3 (en) Bone-inducing protein
WO1988006625A3 (en) Arginine-depleted human tumor necrosis factor
WO1995025749A3 (en) Eating suppressant peptides
ATE82858T1 (en) N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN.
AU5649586A (en) Partially purified bone-inducing factor
BG105764A (en) Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
EP0355460A3 (en) Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
ATE194384T1 (en) TNF-BINDING PROTEINS
NO941186D0 (en) Hormone analogues with multiple CTP extensions
DK395689D0 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF DIABETES MELLITUS
CA2015994A1 (en) Human lactoferrin cdna sequence
ATE79763T1 (en) USE OF AT LEAST ONE CYTOKINE IN THE MANUFACTURE OF A MEDICATION FOR THE SYSTEMIC TREATMENT OF PRAENEOPLASTIC LESIONS.
DE3617753A1 (en) TISSUE PLASMINOGEN ACTIVATOR, THE PHARMACEUTICAL FORMULATIONS CONTAINING IT AND THEIR PRODUCTION AND USE IN HUMAN AND VETERINE MEDICINE
DE68926679D1 (en) PHYSIOLOGICALLY ACTIVE POLYPEPTIDE, RECOMBINANT PLASMIDE, RECOMBINANT MICROBIAL CELLS, MEDICAL PREPARATION AND METHOD FOR OBTAINING THE PURIFIED POLYPEPTIDE
EP0410207A3 (en) Stabilization of highly purified proteins
AU2308992A (en) Cysteine depleted il-6 muteins
AU2670495A (en) Ifn-beta liquid formulations
AU1384995A (en) Human circulating cytokine cc-1
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
DK1040191T3 (en) RANTES mutants and their therapeutic uses
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
DE69128877D1 (en) Pig somatotropins with modifications in the area of Alpha Helix 1 and combinations with other mutations
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE